Antidote-mediated control of an anticoagulant aptamer in vivo

被引:279
作者
Rusconi, CP
Roberts, JD
Pitoc, GA
Nimjee, SM
White, RR
Quick, G
Scardino, E
Fay, WP
Sullenger, BA
机构
[1] Duke Univ, Med Ctr, Dept Surg, Ctr Translat Res, Durham, NC 27710 USA
[2] Univ Michigan, Med Ctr, Dept Internal Med, Ann Arbor, MI 48109 USA
基金
美国国家卫生研究院;
关键词
D O I
10.1038/nbt1023
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Patient safety and treatment outcome could be improved if physicians could rapidly control the activity of therapeutic agents in their patients. Antidote control is the safest way to regulate drug activity, because unlike rapidly clearing drugs, control of the drug activity is independent of underlying patient physiology and co-morbidities. Until recently, however, there was no general method to discover antidote-controlled drugs. Here we demonstrate that the activity and side effects of a specific class of drugs, called aptamers, can be controlled by matched antidotes in vivo. The drug, an anticoagulant aptamer, systemically induces anticoagulation in pigs and inhibits thrombosis in murine models. The antidote rapidly reverses anticoagulation engendered by the drug, and prevents drug-induced bleeding in surgically challenged animals. These results demonstrate that rationally designed drug-antidote pairs can be generated to provide control over drug activities in animals.
引用
收藏
页码:1423 / 1428
页数:6
相关论文
共 30 条
[1]   Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes [J].
Al Suwaidi, J ;
Reddan, DN ;
Williams, K ;
Pieper, KS ;
Harrington, RA ;
Califf, RM ;
Granger, CB ;
Ohman, EM ;
Holmes, DR .
CIRCULATION, 2002, 106 (08) :974-980
[2]   Lowering the hemoglobin threshold for transfusion in coronary artery bypass procedures: effect on patient outcome [J].
Bracey, AW ;
Radovancevic, R ;
Riggs, SA ;
Houston, S ;
Cozart, H ;
Vaughn, WK ;
Radovancevic, B ;
McAllister, HA ;
Cooley, DA .
TRANSFUSION, 1999, 39 (10) :1070-1077
[3]  
Carr JA, 1999, J CARDIOVASC SURG, V40, P659
[4]   Targeted inhibition of intrinsic coagulation limits cerebral injury in stroke without increasing intracerebral hemorrhage [J].
Choudhri, TF ;
Hoh, BL ;
Prestigiacomo, CJ ;
Huang, J ;
Kim, LJ ;
Schmidt, AM ;
Kisiel, W ;
Connolly, ES ;
Pinsky, DJ .
JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 190 (01) :91-99
[5]   PILOT-STUDY OF THE EFFICACY OF A THROMBIN INHIBITOR FOR USE DURING CARDIOPULMONARY BYPASS [J].
DEANDA, A ;
COUTRE, SE ;
MOON, MR ;
VIAL, CM ;
GRIFFIN, LC ;
LAW, VS ;
KOMEDA, M ;
LEUNG, LLK ;
MILLER, DC .
ANNALS OF THORACIC SURGERY, 1994, 58 (02) :344-350
[6]  
DEJANA E, 1982, THROMB HAEMOSTASIS, V48, P108
[7]   Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys [J].
Drolet, DW ;
Nelson, J ;
Tucker, CE ;
Zack, PM ;
Nixon, K ;
Bolin, R ;
Judkins, MB ;
Farmer, JA ;
Wolf, JL ;
Gill, SC ;
Bendele, RA .
PHARMACEUTICAL RESEARCH, 2000, 17 (12) :1503-1510
[8]   Drug-related deaths in a department of internal medicine [J].
Ebbesen, J ;
Buajordet, I ;
Erikssen, J ;
Brors, O ;
Hilberg, T ;
Svaar, H ;
Sandvik, L .
ARCHIVES OF INTERNAL MEDICINE, 2001, 161 (19) :2317-2323
[9]   Effect of blood transfusion on long-term survival after cardiac operation [J].
Engoren, MC ;
Habib, RH ;
Zacharias, A ;
Schwann, TA ;
Riordan, CJ ;
Durham, SJ .
ANNALS OF THORACIC SURGERY, 2002, 74 (04) :1180-1186
[10]   Vitronectin inhibits the thrombotic response to arterial injury in mice [J].
Fay, WP ;
Parker, AC ;
Ansari, MN ;
Zheng, XX ;
Ginsburg, D .
BLOOD, 1999, 93 (06) :1825-1830